Wednesday, July 8, 2026

biotech · Hypertriglyceridemia · Candidiasis, Chronic Mucocutaneous · MTNB

Matinas BioPharma Holdings

Matinas BioPharma is a biotech organization headquartered in Bedminster, USA. It trades on NYSE under ticker MTNB. Primary therapeutic focus areas include Hypertriglyceridemia, Candidiasis, Chronic Mucocutaneous, Cryptoc

Bedminster, USA HQ
2011 Founded
16 Employees
Public company Type
MTNB · NYSE Ticker
Company details
Status
Public
HQ
Bedminster, USA
Founded
2011
Employees
16
Programs
9
Drugs
5
Patents
8
Clinical program

Omega 3 pentaenoic acid

Phase 2 · small molecule · Hypertriglyceridemia

Omega 3 pentaenoic acid for Hypertriglyceridemia is a Phase 2 program (small_molecule) at Matinas BioPharma Holdings with 1 ClinicalTrials.gov record(s).

← All Matinas BioPharma Holdings projects Phase 2 small molecule completed

Internal code MAT-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Matinas BioPharma Holdings
Phase
Phase 2
Modality
small_molecule
Indication
Hypertriglyceridemia
Status
completed
Trials
1